As it advances with a purchase of Intra-Cellular Therapies (NASDAQ:ITCI), Johnson & Johnson (NYSE:JNJ) runs the danger of losing its AAA credit rating. Concerned about the possible increase in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback